Comment on CMS-2026-1255-0001

Summary: Genentech, a biotechnology company, supports the proposed rule but advocates for more robust and specific requirements regarding step therapy and prior authorization. They argue for increased transparency, the prohibition of "embedded" step therapy, the mandatory use of Payer-to-Payer APIs to ensure continuity of care, and strict clinical guardrails to prevent arbitrary coverage denials.